Heparin-binding hemagglutinin, from an extrapulmonary dissemination factor to a powerful diagnostic and protective antigen against tuberculosis

Tuberculosis

Volumn 86, Issue 3-4 SPEC. ISS., 2006, Pages 303-309

  Locht, Camille ^a   Hougardy, Jean Michel ^b   Rouanet, Carine ^a   Place, Sammy ^b   Mascart, Françoise ^b  

^a INSTITUT PASTEUR DE LILLE   (France)

^b ERASME HOSPITAL   (Belgium)

Author keywords

Immuno diagnostics; Latent TB; Protective immune responses; Reactivation; Vaccine

Indexed keywords

ACELLULAR VACCINE; BACTERIAL ANTIGEN; BACTERIAL PROTEIN; BCG VACCINE; CD4 ANTIGEN; CD8 ANTIGEN; DIAGNOSTIC AGENT; DIMETHYLDIOCTADECYLAMMONIUM BROMIDE; GAMMA INTERFERON; GLYCOCONJUGATE; HEMAGGLUTININ; HEPARIN BINDING HEMAGGLUTININ; HEPARIN BINDING PROTEIN; IMMUNOLOGICAL ADJUVANT; MEMBRANE PROTEIN; PERFORIN; PHOSPHORYL LIPID A; UNCLASSIFIED DRUG;

ANTIGENICITY; ARTICLE; BACTERIAL STRAIN; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CYTOTOXICITY; DISEASE MARKER; EPITHELIUM CELL; HUMAN; IMMUNE RESPONSE; IMMUNITY; LATENT PERIOD; LUNG ALVEOLUS EPITHELIUM; MACROPHAGE; METHYLATION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEFICIENCY; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; SERODIAGNOSIS; STATISTICAL SIGNIFICANCE; T LYMPHOCYTE; TH1 CELL; TUBERCULOSIS;

ANIMALS; BIOLOGICAL MARKERS; EPITHELIAL CELLS; HUMANS; IMMUNITY, CELLULAR; INTERFERON TYPE II; INTERFERON-GAMMA; LECTINS; MICE; MYCOBACTERIUM TUBERCULOSIS; T-LYMPHOCYTE SUBSETS; TUBERCULOSIS;

EID: 33646199047     PISSN: 14729792     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tube.2006.01.016     Document Type: Article

References (31)

1. Comstock G.W. Epidemiology of tuberculosis. Am Rev Respir Dis 125 Suppl. (1982) 8-16
2. World Health Organization. Global tuberculosis control: surveillance planning financing. WHO/TB/2003.316. World Health Organization 2003, Geneva, Switzerland.
3. Colditz G.A., Brewer T.F., Berkey C.S., Wilson M.E., Burdick E., Fineberg H.V., et al. Efficacy of BCG vaccination in the prevention of tuberculosis. Meta-analysis of the published literature. J Am Med Assoc 271 (1994) 698-702
4. Brennan M.J. The tuberculosis vaccine challenge. Tuberculosis 85 (2005) 7-12
5. Turner J., Rhoades E.R., Keen M., Belisle J.T., Frank A.A., and Orme I.M. Effective preexposure tuberculosis vaccines fail to protect when they are given in an immunotherapeutic model. Infect Immun 68 (2000) 1706-1709
6. Tuberculosis Prevention Trial, Madras. Trial of BCG vaccines in South India for tuberculosis prevention. Indian J Med Res 72 Suppl. (1980) 1-74
7. Karonga Prevention Trial Group. Ransomised controlled trial of single BCG, repeated BCG, or combined BCG and killed Mycobacterium leprae vaccine for the prevention of leprosy and tuberculosis in Malawi. Lancet 348 (1996) 17-24
8. Russell D.G. Mycobacterium tuberculosis: here today, and here tomorrow. Nat Rev Mol Cell Biol 2 (2001) 569-577
9. Tufariello J.M., Chan J., and Flynn J.L. Latent tuberculosis: mechanisms of host and bacillus that contribute to persistent infection. Lancet Infect Dis 3 (2003) 578-590
10. Barnes P.F., Bloch A.B., Davidson P.T., and Snider D.E. Tuberculosis in patients with human immunodeficiency virus infection. N Engl J Med 324 (1991) 1644-1650
11. Carol M., Lambrechts A., Urbain D., Van Vooren J.-P., Clumeck N., Goldman M., et al. Persistent T cell and B cell activities in the duodenal mucosa of HIV-infected patients. AIDS 12 (1998) 1763-1769
12. Hopewell P.C., and Jasmer R.M. Overview of clinical tuberculosis. In: Cole S.T., Eisenach K.D., McMurray D.N., and Jacobs Jr. W.R. (Eds). Tuberculosis and the tubercle bacillus (2005), ASM Press, Washington, DC 15-31
13. Griffith A.S. Types of tubercle bacilli in human tuberculosis. J Pathol Bacteriol 32 (1929) 813-840
14. Feldman W.H., and Baggenstoss A.H. The residual infectivity of the primary complex of tuberculosis. Am J Pathol 14 (1938) 473-490
15. Opie E.L., and Aronson J.D. Tubercle bacilli in latent tuberculosis lesions and in lung tissue without tuberculous lesions. Arch Pathol Lab Med 4 (1927) 1-21
16. Crandall E.D., and Kim K.J. Alveolar epithelial barrier properties. In: Crystal R.J., and West J.B. (Eds). The lung: scientific foundations (1991), Raven Press, New York 273-287
17. Shepard C.C. Growth characteristics of tubercule bacilli and certain other mycobacteria in HeLa cells. J Exp Med 105 (1957) 39-48
18. Bermudez L.E., and Goodman J. Mycobacterium tuberculosis invades and replicates within type II alveolar cells. Infect Immun 64 (1996) 1400-1406
19. Hernandez-Pando R., Jeyanathan M., Mengistu G., Aguilar D., Orozco H., Harboe M., et al. Persistence of DNA from Mycobacterium tuberculosis in superficially normal lung tissue during latent infection. Lancet 356 (2000) 2133-2137
20. Menozzi F.D., Rouse J.H., Alavi M., Laude-Sharp M., Muller J., Bischoff R., et al. Identification of a heparin-binding hemagglutinin present in mycobacteria. J Exp Med 184 (1996) 229-1001
21. Pethe K., Alonso S., Biet F., Delogu G., Brennan M.J., Locht C., et al. The heparin-binding haemagglutinin of M. tuberculosis is required for extrapulmonary dissemination. Nature 412 (2001) 190-194
22. Mueller-Ortiz S.L., Sepulveda E., Olsen M.R., Jagannath C., Wanger A.R., and Norris S.J. Decreased infectivity despite unaltered C3 binding by a Δ hbhA mutant of Mycobacterium tuberculosis. Infect Immun 70 (2002) 6751-6760
23. Masungi C., Temmerman S., Van Vooren J.-P., Drowart A., Pethe K., Menozzi F.D., et al. Differential T and B cell responses against Mycobacterium tuberculosis heparin-binding hemagglutinin adhesin in infected healthy individuals and patients with tuberculosis. J Infect Dis 185 (2002) 513-520
24. Zanetti S., Bua A., Delogu G., Pusceddu C., Mura M., Saba F., et al. Patients with pulmonary tuberculosis develop a strong humoral response against methylated heparin-binding hemagglutinin. Clin Diagn Lab Immunol 12 (2005) 1135-1138
25. Temmerman S., Pethe K., Parra M., Alonso S., Rouanet C., Pickett T., et al. Methylation-dependent T cell immunity to Mycobacterium tuberculosis heparin-binding hemagglutinin. Nat Med 10 (2004) 935-941
26. Sorensen A.L., Nagai S., Houen G., Andersen P., and Andersen A.B. Purification and characterization of a low-molecular-mass T-cell antigen secreted by Mycobacterium tuberculosis. Infect Immun 63 (1995) 1710-1717
27. + T lymphocytes in latent human tuberculosis. J Infect Dis 192 (2005) 226-232
28. Parra M., Pickett T., Delogu G., Dheenadhayalan V., Debrie A.S., Locht C., et al. The mycobacterial heparin-binding hemagglutinin is a protective antigen in the mouse aerosol challenge model of tuberculosis. Infect Immun 72 (2004) 6799-6805
29. Menozzi F.D., Bischoff R., Fort E., Brennan M.J., and Locht C. Molecular characterization of the mycobacterial heparin-binding hemagglutinin, a mycobacterial adhesin. Proc Natl Acad Sci USA 95 (1998) 12625-12630
30. Pethe K., Bifani P., Drobecq H., Sergheraert C., Debrie A.S., Locht C., et al. Mycobacterial heparin-binding hemagglutinin and laminin-binding protein share antigenic methyllysines that confer resistance to proteolysis. Proc Natl Acad Sci USA 99 (2002) 10759-10764
31. Pethe K., Aumercier M., Fort E., Gatot C., Locht C., and Menozzi F.D. Characterization of the heparin-binding site of the mycobacterial heparin-binding hemagglutinin adhesin. J Biol Chem 12 (2000) 14273-14280